根据最近向证券交易委员会（SEC）提交的8-K文件显示，市值目前为78万美元的Scorpius Holdings, Inc.（SCPX）为精简运营并降低支出，已完成一项重要的租约转让并调整了此前的收购协议条款。根据 InvestingPro 数据，该公司面临短期债务超过流动资产的挑战，当前比率为0.62。

市值780万美元的制药公司Scorpius Holdings, Inc.（NYSE American: SCPX）宣布扩大董事会规模并任命新成员。根据最新的SEC文件显示，该公司于周一将董事会规模扩大至5名成员，并任命陈思川（Tan Sze Thuan）为董事。此次任命之际，公司股价在过去六个月下跌了近82%。

Scorpius Holdings, Inc., a pharmaceutical company with a market capitalization of $1.36 million, has entered into a material definitive agreement through the issuance of a non-convertible ...

In a move to streamline operations and reduce expenses, Scorpius Holdings, Inc. (SCPX), currently valued at $0.78 million in market capitalization, has completed a significant lease assignment and ...

IM-2 launch of Nova-C class lander on March 6 features composite propulsion system infrastructure that will enable successful lunar touchdown, exploration.

There can be no assurance that this process will result in any transaction or other strategic change or as to the timing of any such potential agreement or transaction. Scorpius does not intend to ...

Scorpius Holdings, Inc. DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and ...

Scorpius Holdings, Inc., a pharmaceutical company based in North Carolina, with a current market capitalization of $1.14 million and trailing twelve-month revenue of $10.04 million, has entered ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.